By applying a more stringent statistic cutoff (FDR < 5%) to obtain reliable protein candidates, ARSs, including YARS and tryptophanyl-tRNA synthetase (WARS), were consistently selected as key proteins in breast cancer patients showing good response to chemotherapy (Fig. 1d). Here, YARS1 is linked to breast cancer.